Skip to main content

Advertisement

Table 2 Presence of anti-peptide IgG in sera from patients with SSc or SLE and healthy blood donors, according to the best cutoffs for discriminating ACA-positive from ACA-negative SSc patients

From: Clinical correlates of a subset of anti-CENP-A antibodies cross-reacting with FOXE3p53-62 in systemic sclerosis

IgG specificity Discriminating SSc SLE (n=46) HBD (n=25)
  cutoff (µg/ml)a ACA+
(n= 75)
ACA+
(n=46)
  
Ap1-17+ >10.4 66 (88.0) 1 (2.2) 2 (4.3) 3 (12.0)
Ap17-30+ >1.2 62 (82.6) 2 (4.3) 4 (8.7) 1 (4.0)
FOXE3p53-62+ >74.5 40 (53.3) 5 (10.9) 13 (28.3) 1 (4.0)
FOXE3p53-62+ and Ap1-17+ or Ap17-30+   40 (100)b 0 (0) b 3 (23.1) b 1 (100) b
  1. Values are presented as n (%) from a sample of 121 patients with SSc, 46 patients with SLE, and 25 HBD. aCutoffs were defined using receiver operating characteristic analysis; bpercentage of FOXE3p53-62+ samples that were also positive for Ap1-17 and/or Ap17-30. ACA, anti-centromere-associated protein antibodies; SSc, systemic sclerosis; SLE, systemic lupus erythematosus; HBD, healthy blood donors.